BUZZ-$7 billion could be a 'light' price tag for Lantheus, Truist analysts say

Lantheus Holdings

Lantheus Holdings

LNTH

0.00

Nuclear medicine company Lantheus Holdings LNTH.O was weighing a potential sale, valuing it at about $7 bln, following a takeover offer from private-equity backed Curium Pharma, Bloomberg News reported on Friday

** A $7 billion valuation feels "light" compared to its current market capitalization of about $6.7 billion, Truist analysts say

** LNTH complements Curium's established portfolio of radiopharma products in both neuroendocrine and prostate cancer segments - Truist

** US FDA approved a new formulation of Lantheus' imaging agent, Pylarify TruVu, to detect prostate cancer in March

** LNTH remains "an undervalued & compelling rev/profit growth re-acceleration story amid a diversifying set of growth drivers" and improving reimbursement outlook for its PET imaging franchise - Truist

** Brokerage says investors would consider $115-$125 per share "more palatable premium/takeout level"

** Up to Friday's close, stock up nearly 55% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.